Page last updated: 2024-10-27

fluorouracil and Mandibular Diseases

fluorouracil has been researched along with Mandibular Diseases in 2 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Mandibular Diseases: Diseases involving the MANDIBLE.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Longo, M1
Gouveia Garcia, V1
Ervolino, E1
Ferro Alves, ML1
Duque, C1
Wainwright, M1
Theodoro, LH1
Salama, JK1
Vokes, EE1
Chmura, SJ1
Milano, MT1
Kao, J1
Stenson, KM1
Witt, ME1
Haraf, DJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation[NCT00970502]Phase 1/Phase 215 participants (Actual)Interventional2007-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Toxicity

Number of participants with acute and late toxicity (NCT00970502)
Timeframe: 30 DAYS

Interventionparticipants (Number)
Celecoxib 200mg0
Celecoxib 400mg1
Celecoxib 600mg2

Clinical Response

Response to Concurrent Erlotinib, Celecoxib, and Reirradiation according to Response Evaluation Criteria in Solid Tumors - Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT00970502)
Timeframe: 20 months

InterventionParticipants (Count of Participants)
Complete Response(CR)Pathologic partial response (pPR)Progressive disease (PD)No evidence of disease (NED)
Erlotinib + Celecoxib6152

Locoregional Control, Progression-free Survival, Overall Survival and Late Toxicity

At a median follow-up of 11 months, the 1 year locoregional control, progression-free survival, and overall survival rates. (NCT00970502)
Timeframe: 1 year

Interventionpercentage of participants (Number)
locoregional controlprogress-free survivaloverall survival rateslong term toxicity
Erlotinib + Celecoxib6037550

Locoregional Progression

Patients with locoregional and/or distant progression (NCT00970502)
Timeframe: 20 months

Interventionparticipants (Number)
free of diseaseisolated locoregional progressionisolated distant progressionboth locoregional and distant progressionno evidence of disease, died of comorbid illness
Erlotinib + Celecoxib44213

Other Studies

2 other studies available for fluorouracil and Mandibular Diseases

ArticleYear
Multiple aPDT sessions on periodontitis in rats treated with chemotherapy: histomorphometrical, immunohistochemical, immunological and microbiological analyses.
    Photodiagnosis and photodynamic therapy, 2019, Volume: 25

    Topics: Aggregatibacter actinomycetemcomitans; Alveolar Bone Loss; Animals; Dental Scaling; Disease Models,

2019
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
    International journal of radiation oncology, biology, physics, 2006, Feb-01, Volume: 64, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality

2006